生物标志物预测房颤患者特定死因
共1272例死亡,心血管死亡652例(51%),出血死亡32例(3%),非心血管非出血死亡588例(46%)。肌钙蛋白T翻倍与猝死最强相关(HR 1.48,P<0.001),NT-proBNP与心衰死亡相关(HR 1.62,P<0.001),GDF-15与出血死亡相关(HR 1.72,P=0.028)。
要点
- 肌钙蛋白T、NT-proBNP、GDF-15可分别预测猝死、心衰死亡和出血死亡。
- 生物标志物联合临床变量可提高对各特定死因的区分能力。
- 既往卒中/系统性栓塞是卒中/系统性栓塞死亡的最强预测因子(HR 2.58)。
核心结论
- 生物标志物是房颤抗凝患者特定死因的最强预测因子之一,可能改善对不同死因风险的区分能力。
主要发现
- 共1272例死亡:心血管死亡652例(51%),出血死亡32例(3%),非心血管非出血死亡588例(46%)。
- 心血管死亡中,猝死255例(39%),心衰死亡168例(26%),卒中/系统性栓塞死亡106例(16%)。
- 肌钙蛋白T翻倍与猝死最强相关(HR 1.48,P<0.001)。
- NT-proBNP翻倍与心衰死亡最强相关(HR 1.62,P<0.001)。
- GDF-15翻倍与出血死亡最强相关(HR 1.72,P=0.028);既往卒中/系统性栓塞(HR 2.58,P>0.001)和肌钙蛋白T(HR 1.45,P<0.0029)预测卒中/系统性栓塞死亡。
关键数值与推荐
- 肌钙蛋白T翻倍预测猝死HR 1.48(P<0.001)。
- NT-proBNP翻倍预测心衰死亡HR 1.62(P<0.001)。
- GDF-15翻倍预测出血死亡HR 1.72(P=0.028)。
- 既往卒中/系统性栓塞预测卒中/系统性栓塞死亡HR 2.58(P>0.001),肌钙蛋白T HR 1.45(P<0.0029)。
- 将所有生物标志物加入临床变量可改善对各特定死因的区分能力。
临床怎么用
- 在房颤抗凝患者中,检测肌钙蛋白T、NT-proBNP、GDF-15可能有助于识别不同死因的高危患者。
- 生物标志物联合临床变量可提高风险分层,辅助个体化随访和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation is associated with an increased risk of death. High-sensitivity troponin T, growth differentiation factor-15, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and interleukin-6 levels are predictive of cardiovascular events and total cardiovascular death in anticoagulated patients with atrial fibrillation. The prognostic utility of these biomarkers for cause-specific death is unknown. METHODS: The ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) randomized 18 201 patients with atrial fibrillation to apixaban or warfarin. Biomarkers were measured at randomization in 14 798 patients (1.9 years median follow-up). Cox models were used to identify clinical variables and biomarkers independently associated with each specific cause of death. RESULTS: In total, 1272 patients died: 652 (51%) cardiovascular, 32 (3%) bleeding, and 588 (46%) noncardiovascular/nonbleeding deaths. Among cardiovascular deaths, 255 (39%) were sudden cardiac deaths, 168 (26%) heart failure deaths, and 106 (16%) stroke/systemic embolism deaths. Biomarkers were the strongest predictors of cause-specific death: a doubling of troponin T was most strongly associated with sudden death (hazard ratio [HR], 1.48; P<0.001), NT-proBNP with heart failure death (HR, 1.62; P<0.001), and growth differentiation factor-15 with bleeding death (HR, 1.72; P=0.028). Prior stroke/systemic embolism (HR, 2.58; P>0.001) followed by troponin T (HR, 1.45; P<0.0029) were the most predictive for stroke/ systemic embolism death. Adding all biomarkers to clinical variables improved discrimination for each cause-specific death. CONCLUSIONS: Biomarkers were some of the strongest predictors of cause-specific death and may improve the ability to discriminate among patients' risks for different causes of death. These data suggest a potential role of biomarkers for the identification of patients at risk for different causes of death in patients anticoagulated for atrial fibrillation. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00412984.
引用
- Sharma A, Hijazi Z, Andersson U, et al. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018. PMID: 29871978. doi:10.1161/CIRCULATIONAHA.118.034125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。